Recent research suggests a multimodal approach to the diagnosis and management of prostatic carcinoma, involving multiparametric magnetic resonance imaging (mpMRI), prostate-specific membrane antigen (PSMA) positron emission tomography (PET/CT), and the fusion-guided prostatic biopsy technique [6]. The gene discussed is FOLH1; the disease is prostate carcinoma.